Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/Ib trial identifies the side effects and best dose of abemaciclib when given together with olaparib in treating patients with ovarian cancer that responds at first to treatment with drugs that contain the metal platinum but then comes back within a certain period (recurrent platinum-resistant). Abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. Adding abemaciclib to olaparib may work better to treat recurrent platinum-resistant ovarian cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony histologicznie nawrotowy rak jajnika, który wrócił w ciągu 6 miesięcy po ostatniej chemioterapii opartej na platynie
- •Wcześniejsze leczenie systemowe: od 1 do 3 poprzednich therapii
- •Wiek minimum 18 lat
- •Ogólny stan zdrowia pozwalający na leczenie (ECOG 0-2)
- •Hemoglobina powyżej 10 g/dL
- •Liczba neutrofili powyżej 1500/mcL
- •Liczba płytek krwi powyżej 100 000/mcL
- •Prawidłowe wyniki funkcji wątroby i nerek
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (27)
Mayo Clinic Hospital in Arizona
Phoenix, United States
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, United States
Los Angeles General Medical Center
Los Angeles, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, United States
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, United States
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, United States
Mayo Clinic in Florida
Jacksonville, United States
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, United States
Northwestern University
Chicago, United States
University of Kansas Clinical Research Center
Fairway, United States
University of Kansas Cancer Center
Kansas City, United States
University of Kansas Cancer Center-Overland Park
Overland Park, United States
University of Kansas Hospital-Indian Creek Campus
Overland Park, United States
University of Kansas Hospital-Westwood Cancer Center
Westwood, United States
Mayo Clinic in Rochester
Rochester, United States
University of Kansas Cancer Center - North
Kansas City, United States
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, United States
University of Kansas Cancer Center at North Kansas City Hospital
North Kansas City, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Wake Forest University Health Sciences
Winston-Salem, United States
Ohio State University Comprehensive Cancer Center
Columbus, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Thomas Jefferson University Hospital
Philadelphia, United States
Vanderbilt University/Ingram Cancer Center
Nashville, United States
University of Virginia Cancer Center
Charlottesville, United States
Trial contact
Site Public Contact
Sami Dwabe
PRINCIPAL_INVESTIGATOR
Site Public Contact
Anastasia Martynova
PRINCIPAL_INVESTIGATOR
Site Public Contact
Site Public Contact
Andrea D. Jewell
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrea E. Wahner Hendrickson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Janelle Darby
PRINCIPAL_INVESTIGATOR
Site Public Contact
John L. Hays
PRINCIPAL_INVESTIGATOR
Site Public Contact
Lauren E. Dockery
PRINCIPAL_INVESTIGATOR
Site Public Contact
Mitchell I. Edelson
PRINCIPAL_INVESTIGATOR
Site Public Contact
Alaina J. Brown
PRINCIPAL_INVESTIGATOR
Site Public Contact
Linda R. Duska
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/9/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.